Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

SER

Serina Therapeutics Inc

Dec 06 • 04:00PM ET

5.51

Dollar change -0.32
Percentage change -5.57	%

Healthcare • Biotechnology • USA • AMEX

Peers: MRK LLY BMY JNJ AMGN PFE GILD REGN VRTX BIIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.94	Insider Own	54.91%	Shs Outstand	8.89M	Perf Week	4.95%
Market Cap	46.26M	Forward P/E	-	EPS next Y	-	Insider Trans	1.44%	Shs Float	4.01M	Perf Month	-9.82%
Income	-6.28M	PEG	-	EPS next Q	-	Inst Own	3.41%	Short Float	0.80%	Perf Quarter	-30.88%
Sales	0.13M	P/S	355.86	EPS this Y	-	Inst Trans	49.55%	Short Ratio	1.41	Perf Half Y	-39.38%
Book/sh	-1.55	P/B	-	EPS next Y	-	ROA	-63.92%	Short Interest	0.03M	Perf Year	-60.83%
Cash/sh	0.38	P/C	14.50	EPS next 5Y	-	ROE	-	52W Range	3.81 - 22.83	Perf YTD	-59.31%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-12.67%	ROI	-	52W High	-75.86%	Beta	0.94
Dividend TTM	-	Quick Ratio	0.40	Sales past 5Y	-39.80%	Gross Margin	-36.51%	52W Low	44.62%	ATR (14)	0.72
Dividend Ex-Date	-	Current Ratio	0.40	EPS Y/Y TTM	55.34%	Oper. Margin	-11951.59%	RSI (14)	49.36	Volatility	17.64% 15.28%
Employees	4	Debt/Eq	-	Sales Y/Y TTM	34.04%	Profit Margin	-4983.33%	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	102.62%	Payout	-	Rel Volume	0.63	Prev Close	5.84
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-79.10%	Earnings	-	Avg Volume	22.70K	Price	5.51
SMA20	8.64%	SMA50	-11.18%	SMA200	-39.31%	Trades		Volume	14,395	Change	-5.57%

Dec-02-24 05:22PM	Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients (GlobeNewswire) -9.52% +19.16%
Nov-12-24 05:00PM	Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-11-24 05:40PM	Serina Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) +20.87%
Oct-02-24 08:30AM	Serina Therapeutics to Present at the 14th Annual Injectables Summit (GlobeNewswire)
Sep-04-24 06:42PM	Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
07:01PM	Loading…
Aug-20-24 07:01PM	Director Gregory Bailey Acquires 19,200 Shares of Serina Therapeutics Inc (SER) (GuruFocus.com)
Aug-09-24 04:15PM	Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire) -5.17% -10.13%
Jul-29-24 08:30AM	Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit (GlobeNewswire)
Jul-18-24 05:00PM	Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation (GlobeNewswire) -18.15% +9.84%
May-15-24 07:30AM	Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse® for Advanced Parkinsons Disease (GlobeNewswire)
May-14-24 04:05PM	Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire) +11.13%
Apr-17-24 04:05PM	Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman (GlobeNewswire) -9.64%
Mar-26-24 05:04PM	Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics (GlobeNewswire) -11.90% +33.98%

Serina Therapeutics, Inc. operates as a pharmaceutical company, which engages in the development of polymer technology. Its POZ technology is designed to optimize drug delivery to maximize compliance, therapeutic outcomes, safety, and quality of life for patients. It also offers drugs to treat neurological diseases, cancer, and pain. The company was founded by J. Milton Harris and Michael D. Bentley on March 26, 2024 and is headquartered in Huntsville, AL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bailey Gregory	Director	Sep 20 '24	Buy	6.03	1,137	6,851	63,377	Sep 24 04:30 PM
Bailey Gregory	Director	Sep 19 '24	Buy	6.11	11,679	71,384	62,240	Sep 20 06:59 PM
Bailey Gregory	Director	Sep 18 '24	Buy	6.23	2,709	16,873	50,561	Sep 20 06:59 PM
MINTZ STEVEN	Director	Sep 12 '24	Buy	6.47	6,000	38,814	17,443	Sep 16 06:53 PM
Bailey Gregory	Director	Aug 20 '24	Buy	8.25	1,776	14,652	47,582	Aug 22 05:27 PM
Bailey Gregory	Director	Aug 19 '24	Buy	7.93	6,400	50,760	45,806	Aug 20 04:35 PM
Bailey Gregory	Director	Aug 16 '24	Buy	7.31	6,400	46,780	39,406	Aug 20 04:35 PM
Bailey Gregory	Director	Aug 15 '24	Buy	6.65	6,400	42,577	33,006	Aug 20 04:35 PM
MINTZ STEVEN	Director	Aug 15 '24	Buy	6.59	7,593	50,033	11,443	Aug 19 06:55 PM
MINTZ STEVEN	Director	Aug 15 '24	Buy	6.59	1,350	8,896	12,257	Aug 19 06:55 PM
Bailey Gregory	Director	Aug 14 '24	Buy	7.07	6,400	45,228	26,606	Aug 16 04:20 PM
MINTZ STEVEN	Director	Jun 21 '24	Buy	9.50	5,000	47,500	8,307	Jun 27 08:26 PM
MINTZ STEVEN	Director	Jun 25 '24	Buy	9.00	2,600	23,400	10,907	Jun 27 08:26 PM
Bailey Gregory	Director	May 30 '24	Buy	9.50	5,205	49,448	20,206	May 31 04:18 PM
Bailey Gregory	Director	May 29 '24	Buy	9.50	1,173	11,144	15,001	May 31 04:18 PM
Bailey Gregory	Director	May 28 '24	Buy	9.50	9,019	85,680	13,828	May 29 04:15 PM
Bailey Gregory	Director	May 23 '24	Buy	9.50	2,371	22,524	4,809	May 24 04:15 PM
Bailey Gregory	Director	May 21 '24	Buy	9.50	916	8,702	2,438	May 24 04:15 PM
MINTZ STEVEN	Director	May 21 '24	Buy	9.93	9,151	90,885	9,900	May 23 05:07 PM
MINTZ STEVEN	Director	May 20 '24	Buy	9.43	2,675	25,233	1,240	May 23 05:07 PM
MINTZ STEVEN	Director	May 17 '24	Buy	8.50	554	4,709	554	May 23 05:07 PM
Bailey Gregory	Director	May 21 '24	Buy	9.50	1,422	13,509	1,522	May 23 04:15 PM
Bailey Gregory	Director	May 20 '24	Buy	9.00	100	900	100	May 22 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SER

Serina Therapeutics Inc

Upgrade your FINVIZ experience